<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02898805</url>
  </required_header>
  <id_info>
    <org_study_id>AKP_3</org_study_id>
    <nct_id>NCT02898805</nct_id>
  </id_info>
  <brief_title>Effects of LopiGLIK® on Cardiovascular Risk</brief_title>
  <acronym>LopiWEB</acronym>
  <official_title>Effects of a New Combination of Nutraceutics (LopiGLIK®) on Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to compare the effects of two combination of nutraceuticals: Armolipid
      Plus® and LopiGLIK® (Akademy Pharma), a new supplement that, in addition to Berberine and Red
      Rice, contains Morus Alba's extract. The study will analyze the impact of 16 week treatment
      with one of the combinations, according to a randomized scheme, on metabolic parameters in
      dyslipidemic subjects that do not require or not tolerate a statin therapy. In particular, it
      will assess the ability of the two combinations to reduce the levels of total and LDL
      cholesterol, HbA1C, glicaemia and insulin and increase those of HDL cholesterol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The experimental design involves the construction of a multi-center, controlled, randomized,
      single-blind, versus Armolipid Plus®.

      Patients with mild hypercholesterolemia, of both sexes and aged between 18 and 75 years, will
      be recruited, from the beginning of the study and for the next 2 weeks, from 30 Cv
      specialists and/or GPs (25 patients each).

      The subjects will be enrolled in the 50/50% male/female ratio ± 10% comparable for age, in
      order to obtain a proper comparison between groups with similar demographic characteristics
      or not statistically different.

      The subjects, selected on the basis of inclusion and exclusion criteria, will be divided into
      two groups, subjected to centralized randomization at the &quot;Diagnosis and Treatment of
      hypertension Center&quot; to receive one of two different treatments, a tablet/day of the new
      nutraceutical LopiGLIK® (Akademy Pharma) containing Morus Alba, immediately after a meal, vs.
      a tablet/day of Armolipid Plus, always immediately after the meal. During the first two weeks
      both groups will follow the prescribed diet and assume the placebo. At the end, blood tests
      (traditional metabolic parameters, blood glucose, HbA1C, fasting insulin, transaminase
      levels, CPK) and the endothelial function will be assesed. During the next 16 weeks a group
      will assume LopiGLIK® (Akademy Pharma) containing Morus Alba, the other will assume Armolipid
      Plus and everyone will continue to follow the prescribed diet. At the end of this period
      blood tests will be repeated. Tablets of Armolipid Plus, LopiGLIK® and placebo will be
      provided by Akademy Pharma free of charge
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of LDL-Cholesterol levels</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increasing of HDL-Cholesterol levels</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of HbA1c levels</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of fastin insuline levels</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Cardiovascular Risk Factors</condition>
  <arm_group>
    <arm_group_label>LopiGLIK®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>first two weeks: Placebo + prescribed Diet then 16 weeks LopiGLIK® a tablet/day after a meal + Diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Armolipid Plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>first two weeks: Placebo + prescribed Diet then 16 weeks Armolipid Plus a tablet/day after a meal + Diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>LopiGLIK®</arm_group_label>
    <arm_group_label>Armolipid Plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prescribed Diet</intervention_name>
    <arm_group_label>LopiGLIK®</arm_group_label>
    <arm_group_label>Armolipid Plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LopiGLIK®</intervention_name>
    <arm_group_label>LopiGLIK®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Armolipid Plus</intervention_name>
    <arm_group_label>Armolipid Plus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Total Cholesterol&lt;300 mg/dL

          -  Total Cholesterol&gt;200 mg/dL

          -  Cardiovascular Risk&lt;20%

        Exclusion Criteria:

          -  Pregnancy

          -  Documented intolerance to one or more 'components LOPIGLIK / Armolipid PLUS

          -  Previous cardiovascular events

          -  Familiar severe dyslipidemia

          -  Familiar high cardiovascular risk Hepatic or muscular disorders Subjects receiving
             lipid-lowering drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Trimarco, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>FEDERICO II UNIVERSITY - NAPLES</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Trimarco, Professor</last_name>
    <phone>+39 081 746 22 50</phone>
    <email>trimarco@unina.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raffaele Izzo, Professor</last_name>
    <phone>+39 081 746 2211</phone>
    <email>rafizzo@unia.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federico II University</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Izzo, Professor</last_name>
      <phone>+39 081 746 2211</phone>
      <email>rafizzo@unina.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Trimarco V, Izzo R, Stabile E, Rozza F, Santoro M, Manzi MV, Serino F, Schiattarella GG, Esposito G, Trimarco B. Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial. High Blood Press Cardiovasc Prev. 2015 Jun;22(2):149-54. doi: 10.1007/s40292-015-0087-2. Epub 2015 Apr 14.</citation>
    <PMID>25870124</PMID>
  </results_reference>
  <results_reference>
    <citation>Carrizzo A, Ambrosio M, Damato A, Madonna M, Storto M, Capocci L, Campiglia P, Sommella E, Trimarco V, Rozza F, Izzo R, Puca AA, Vecchione C. Morus alba extract modulates blood pressure homeostasis through eNOS signaling. Mol Nutr Food Res. 2016 Oct;60(10):2304-2311. doi: 10.1002/mnfr.201600233. Epub 2016 Jun 27.</citation>
    <PMID>27234065</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Bruno Trimarco</investigator_full_name>
    <investigator_title>PROF OF CARDIOLOGY</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data available to principal investigator</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

